Treating wet AMD with radiation


A single procedure may be as effective as repeated anti-VEGF injections claims Timothy L. Jackson.

Key Points

Choroidal neovascularization (CNV) is a result of over-expression of vascular endothelial growth factor, recruitment of inflammatory cells, and fibroblasts. Radiation is known preferentially to damage proliferating endothelial cells. Epimacular brachytherapy is an AMD therapy that utilizes a novel surgical device to deliver targeted beta radiation to active AMD lesions. Unlike anti-VEGF agents, radiation is thought to eliminate CNV vessels permanently, rather than simply suppress them. For this reason, the device offers the prospect of a one-off operation, rather than a lifetime of intravitreal injections entailing considerable expense, patient inconvenience, and a small but cumulative risk of complications.

Early studies of radiation

Successive attempts to provide a more focal delivery under the retina had only limited success, as the very process of accessing the subretinal space caused damage. By contrast, epimacular brachytherapy - which involves the delivery of beta radiation via a vitrectomy procedure - has the potential to provide a highly targeted delivery of beta radiation without surgical damage to the retina.

Details of the procedure

The device consists of a hand piece with a 20-gauge cannula, within which resides a retractable radiation source (the radioactive isotope strontium-90).

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.